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A B S T R A C T   
Purpose: To assess the prognostic role of different inter and intralesional expression (heterogeneity) of oestrogen 
receptor (ER) in bone metastases, as identified by the combined use of [18F]FES PET/CT and [18F]FDG PET/CT 
in patients with oestrogen receptor-positive (ER+) metastatic breast cancer (BC). 
Methods: We analysed patients with a new diagnosis of bone metastases who were candidates for first-line sys-
temic endocrine therapy. Before starting therapy, patients underwent baseline [18F]FES PET/CT and [18]FDG 
PET/CT. Semi-quantitative evaluation of whole-body bone metabolic burden (WB-B-MB) was performed on 
[18F]FES and [18F]FDG PET/CT in order to evaluate disease extent, tumour metabolism and ER heterogeneity. 
We used time-to-event analyses (Kaplan-Meier and Cox proportional-hazards methods) to estimate progression- 
free (PFS) and overall survival (OS), in order to assess the independent prognostic value of [18F]FES PET/CT and 
[18F]FDG PET/CT, alone and in combination. 
Results: According to our criteria, we enrolled 49 patients. Over a median follow-up of 44.7 months, 35 patients 
suffered disease progression (71.4 %) and 15 died of disease (30.6 %). When the risk of disease progression was 
calculated by means of the Cox model, only [18F]FDG WB-B-MB was independently and directly associated to 
PFS (p = 0.02). 
On analysing the association between all prognostic parameters and survival, the Cox model showed that the 
only parameter associated with OS was the WB-B-MB FES/FDG ratio (p = 0.01). 
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Conclusion: The combined use of [18F]FES-PET/CT and [18F]FDG-PET/CT can identify ER heterogeneity in BC 
bone metastases. This heterogeneity is significantly associated with survival. Moreover, the extension of the FDG- 
avid component correlates with the risk of disease progression.   
1. Introduction 
Bone metastases are a prominent cause of morbidity and mortality in 
cancer [1]. In particular, bone is the privileged metastatic location for 
endocrine-sensitive breast cancer (BC) [2–4]. Although the reasons for 
the preferential homing of BC cells towards the skeleton are still unclear, 
it seems plausible that bone marrow niches offer a suitable 
micro-environment for tumour survival [5,6]. Moreover, there is clinical 
evidence that BC expressing oestrogen receptors (ERs) has a higher 
tendency toward skeletal spread than other BC subtypes [7], which tend 
to colonize visceral organs [8]. 
In patients with endocrine-sensitive (ER+) BC, sensitive non- 
invasive biomarkers that can evaluate the presence and extension of 
bone metastases, together with their ER expression, are required. 
Indeed, approximately 70 % of BCs are considered endocrine-sensitive, 
on the basis of the expression of hormonal receptors on primary tumour. 
However, endocrine therapy is effective in only about 50 % of 
ER + patients with metastases [9]. In this setting, the early identifica-
tion of patients with ER + metastases who are not going to respond to 
endocrine therapy could avoid ineffective therapies and related toxic-
ities, while prompting the earlier use of more efficacious treatments. 
In recent years, [18F] Fluorine-oestradiol ([18F]FES) PET/CT has 
been proposed as an effective imaging procedure in detecting 
ER + metastases and predicting response to endocrine therapy [10]. 
Indeed, this whole-body imaging may provide excellent information 
about ER expression heterogeneity both within a given tumour and 
across multiple metastases in the same patient [11]. Although the 
sensitivity of [18F]FDG-PET/CT has proved higher than that of [18F] 
FES PET/CT, especially in the case of liver metastases [12–14], [18F] 
FES PET-CT is a reliable imaging procedure with high sensitivity espe-
cially in detecting bone metastases [12,13], guiding patient manage-
ment [14] and predicting response to endocrine therapy [15]. In 
addition, in the particular setting of patients affected by invasive lobular 
carcinoma, which has indolent growth and low tumour glycolysis, [18F] 
Fig. 1. The scoring system divides the skeleton into 8 anatomic segments. The disease extension (DE) score is graded as: 0, no sites per segment; 1, one discrete site 
per segment; 2, two discrete lesions; 3, three discrete lesions; 4, >3 discrete foci or a single lesion involving <50 % of a bone; 5, involvement of 50–95 % of the whole 
bone; 6, involvement of the entire bone (A). To obtain the bone metabolic burden (B-MB), we multiplied the highest mean standardized uptake value (SUVmean) by 
the DE of each bone segment. The whole-body bone metabolic burden (WB-B-MB) was calculated as the sum of the B-MB of each bone segment. 
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FES PET-CT can better reflect the metastatic burden than [18F] 
FDG-PET/CT [11,16]. 
Although, considerable inter- and intra-patient heterogeneity in 
[18F]FES uptake at different metastatic sites has been reported [13], no 
conclusive data on the association of positive [18F]FES PET/CT with 
progression-free survival (PFS) and overall survival (OS) are as yet 
available [17]. Therefore, [18F]FDG-PET/CT has been proposed as an 
additional tool to identify patients and metastases at higher risk of 
progression (i.e. low ER expression and high glycolytic activity). 
The aim of our study was to assess the association between [18F]FES 
PET/CT and survival indices (i.e. PFS and OS) in ER-positive, Human 
Epidermal Growth Factor Receptor 2 (HER2)-negative BC patients with 
bone metastases undergoing endocrine therapy. We also aimed to 
evaluate the prognostic role of ER heterogeneity in bone metastases, as 
identified by the combined use of [18F]FES PET/CT and [18F]FDG PET/ 
CT. 
2. Materials and methods 
2.1. Patients 
We retrospectively analysed patients with a new diagnosis of bone 
metastases from ER-positive BC who were candidates for first-line 
endocrine therapy. Patients had been prospectively enrolled in a phase 
II multicentre international randomized clinical study (ET-FES JTC 2011 
TRANSCAN project, EUDRACT number 2013-000287-29), the principal 
aim of which was to predict the efficacy of hormonal therapy in ER+, 
HER2- metastatic BC patients and validate the indication for [18F]FES 
PET/CT. The local ethics committees and the public medical agencies of 
the countries involved approved the study. All subjects provided written 
informed consent. 
2.2. Imaging 
At the baseline, all patients underwent [18F]FDG PET/CT and [18F] 
FES PET/CT within 10 days of each other; no treatment was 
administered between the two scans. Image acquisition was performed 
according to standard procedures [15,18]. 
Whole-body [18F]FDG PET/CT was carried out in fasting condition, 
60 min after tracer injection. Data were acquired in the three- 
dimensional mode by means of dedicated PET/CT systems (the first 
Nuclear Medicine Department used Discovery ST, GE Medical Systems; 
the second used Discovery LS, GE Medical Systems; and the third Bio-
graph mCT Flow, Siemens Medical Solutions). The activity administered 
was calculated according to the patient’s body weight [18]. Whole-body 
[18F]FDG PET/CT images were acquired from the base of the skull to 
the mid-thigh and were reconstructed by means of an iterative algo-
rithm. A non-diagnostic CT scan (low-dose CT with 120 kV, 80 mA) was 
used for attenuation correction and for anatomical localization of tracer 
uptake. 
[18F]FES PET/CT acquisitions started 60 min after the injection of 
200 MBq of [18F]FES. A low-dose CT-scan was used for attenuation 
correction in all patients. Patients were scanned from the base of the 
skull to the mid-thigh for 3 min per bed position [15]. 
2.3. Scoring 
The ability of [18F]FDG PET/CT and [18F]FES PET/CT to detect 
Table 1 
Patients’ characteristics.  
N (%) 49 (100.0) 
Age at onset of disease (years)  
mean (SD) 58.2 (13.0) 
ER expression  
median (Q1–Q3) 80.0 (60.0–90.0) 
Ki67 (%)  
median (Q1–Q3) 20.0 (10.0–25.0) 
Visceral MTS, n(%)  
no 16 (32.7) 
yes 33 (67.3) 
FDG, n(%)  
neg 3 (6.1) 
pos 46 (93.9) 
SUV mean FDG  
median (Q1–Q3) 4.2 (3.2–5.5) 
DE FDG  
median (Q1–Q3) 4.0 (2.0–16.0) 
WB-B-MB FDG  
median (Q1–Q3) 17.6 (6.4–83.1) 
FES, n(%)  
neg 7 (14.3) 
pos 42 (85.7) 
SUV mean FES  
median (Q1–Q3) 3.4 (1.8–4.9) 
DE FES  
median (Q1–Q3) 5.0 (1.0–19.0) 
WB-B-MB FES  
median (Q1–Q3) 13.3 (4.0–75.3) 
WB-B-MB ratio FES/FDG  
median (Q1–Q3) 1.1 (0.4–2.1) 
Note 1: SD = standard deviation; (Q1) = 1st quartile; (Q3) = 3rd quartile. 
Table 2 
Factors influencing PFS.   
Incidence rate X 100 patients/ 
month 
95 %CI p- 
value 
Overall 3.6 2.6–5.0 – 
Age at onset of disease 
(years)   
0.604 
≤ 57 3.2 2.0–5.1  
> 57 4.0 2.5–6.4  
ER Expression   0.539 
≤80.0 3.1 2.0–4.9  
> 80.0 4.3 2.7–7.1  
Ki67 (%)   0.528 
≤ 20.0 4.1 2.7–6.2  
> 20.0 2.9 1.6–5.1  
Visceral MTS, n(%)   0.464 
no 4.4 2.5–7.8  
yes 3.3 2.2–4.9  
FDG, n(%)   0.639 
neg 2.1 0.5–8.3  
pos 3.7 2.7–5.3  
SUV mean FDG   0.148 
≤ 4.2 2.9 1.7–4.7  
> 4.2 4.4 2.9–6.9  
DE FDG   0.123 
≤ 4.0 2.7 1.6–4.4  
> 4.0 5.0 3.2–7.9  
WB-B-MB FDG   0.145 
≤ 17.6 2.7 1.7–4.4  
> 17.6 5.0 3.2–7.8  
FES, n(%)   0.612 
Neg 4.3 1.8–10.4  
Pos 3.5 2.4–5.0  
SUV mean FES   0.533 
≤ 3.4 3.9 2.5–6.1  
> 3.4 3.2 1.9–5.3  
DE FES   0.663 
≤ 5.0 3.2 2.1–5.1  
> 5.0 4.1 2.5–6.7  
WB-B-MB FES   0.665 
≤ 13.3 3.9 2.5–6.2  
> 13.3 3.3 2.0–5.3  
WB-B-MB ratio FES/FDG   0.103 
≤1.1 5.0 3.2–7.8  
> 1.1 2.6 1.6–4.3  
Note 1: Median follow-up (months) is calculated on the proportion of subjects 
who did not have disease progression: 42.3 months. 
Note 2: qualitative variables are dichotomized by using the median value. Note 
3: p-values are referred to log-rank test. 
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breast cancer metastases was assessed by reviewing the uptake patterns 
of each radio-pharmaceutical. The mean standard uptake value (SUV-
mean) of the bone lesions was recorded in each patient. A semi- 
quantitative scoring system was applied to [18F]FDG PET/CT and 
[18F]FES PET/CT, in order to evaluate disease extension. The skeletal 
distribution of each tracer was recorded in 8 segments: skull, thoracic 
cage, right humerus, left humerus, spine, pelvis, right femur and left 
femur (Fig. 1). The extent of skeletal involvement in each bone segment 
was scored on a 0–6 scale. Each segment was scored as previously 
validated [19] : 0 (no involvement), 1 (one discrete lesion), 2 (two 
discrete lesions), 3 (three discrete lesions), 4 (>3 discrete foci or a single 
diffuse lesion involving <50 % of a bone region), 5 (involvement of 
50–95 % of a bone region), 6 (involvement of the entire bone region). 
For both tracers, disease extension (DE) was calculated as the sum of 
the scores. To calculate the bone metabolic burden (B-MB), we multi-
plied the score of each segment by the SUVmean of a tumour iso- 
contour, which was generated by setting the threshold at 40 % of the 
maximum SUV. The whole-body bone metabolic burden (WB-B-MB) was 
calculated as the sum of the B-MB [19]. In the case of a negative PET/CT 
result, the SUVmean, DE and WB-B-MB were assigned values of 1. [18F] 
FDG-PET/CT and [18F]FES-PET/CT images were interpreted after a 
consensus reading by two expert nuclear medicine physicians (GB and 
AP), who were aware of the patient’s clinical history and of the results of 
morphological imaging modalities (MRI/CT). 
To express a single score that took into account the results of both 
PET/CT scans in each patient, we finally calculated the ratio between 
the WB-B-MB of [18F]FES PET/CT and that of [18F]FDG PET/CT (WB- 
B-MB Ratio FES/FDG). 
2.4. Treatment 
All patients enrolled in this study received endocrine therapy, as 
clinically indicated [DOI: https://doi.org/10.1200/JCO.2016.67.1487]. 
However, the choice of agents was left to the clinical judgement of the 
treating physician, according to local clinical practice. Treatment was 
discontinued in the event of disease progression, unacceptable toxicity, 
patient refusal or decision of the treating physician. 
2.5. Standard of reference 
Follow-up based on contrast-enhanced CT and [18F]FDG PET/CT 
every 3 months served as the standard of reference for the final diagnosis 
of disease progression. 
Disease progression was defined as an increase in the diameters of 
visceral metastases, according to the RECIST criteria [20], and/or the 
appearance of one or more new metastases [19,21]. Death due to disease 
was recorded when the patient’s death was related to BC. 
2.6. Statistical analysis 
Descriptive statistics included mean, standard deviation, median, 
and 25th and 75th percentiles for continuous variables; in the case of 
categorical variables, absolute and relative values were used. Fisher’s 
exact test and Kruskal-Wallis or t-tests were used to compare categorical 
and continuous variables, respectively. The Kaplan-Meier method was 
used to estimate the cumulative probability of PFS – defined as the in-
terval between the initial diagnosis and the onset of progression of 
disease or death – and OS from the initial diagnosis to the date of death. 
A log-rank test was used to calculate differences between time-to-event 
curves. The Cox proportional-hazards model was used to estimate the 
risk of disease progression and death from any cause, after adjusting for 
the risk factors considered. 
Since [18F]FDG PET/CT and [18F]FES PET/CT scores were highly 
correlated with WB-B-MB ratio (FES/FDG), in order to avoid collin-
earity, we used different models for each score, to test their independent 
association with PFS and OS. All analyses were conducted by means of 
Stata (version 14, StataCorp., College Station, TX, USA) software. Two- 
tailed probabilities are reported and a p-value of 0.05 was used to define 
nominal statistical significance. 
3. Results 
Of the 81 patients included in the ET-FES JTC 2011 TRANSCAN 
project, we retrospectively evaluated 49 according to our criteria. All 49 
presented metastatic breast cancer (MBC) with ascertained bone 
involvement. All patients with visceral or soft tissue metastases without 
skeletal involvement were excluded. The principal characteristics of 
these patients are summarized in Table 1. [18F]FDG PET/CT identified 
bone metastases in 46 patients, and [18F]FES PET/CT in 42. However, 
all patients showed at least one positive bone metastasis on either [18F] 
FDG PET/CT or [18F]FES PET/CT. Six of the 7 patients with negative 
bone involvement on [18F]FES PET/CT also had FES-negative visceral 
metastases. All 3 patients with negative bone involvement on [18F]FDG 
PET/CT also had FDG-negative visceral metastases. 
Over a median follow-up of 44.7 months (interquartile 
range = 35.2–48.2), 35 patients suffered disease progression (71.4 %) 
and 15 died of disease (30.6 %). Disease progression was observed in 33 
of the 46 patients (71.7 %) with positive bone findings on [18F]FDG 
PET/CT and 15 (32.6 %) died of disease. Disease progression was 
Table 3 
Factors influencing OS.   
Incidence rate X 100 patients/ 
month 
95 %CI p-value 
Overall 0.9 0.5–1.5 – 
Age at onset of disease 
(years)   
0.460 
<= 57 1.0 0.5–2.0  
> 57 0.7 0.3–1.6  
ER Expression   0.569 
<= 80.0 0.8 0.4–1.6  
> 80.0 1.0 0.5–2.1  
Ki67 (%)   1.000 
<= 20.0 0.9 0.5–1.7  
> 20.0 0.9 0.4–2.0  
Visceral MTS, n(%)   0.824 
no 1.0 0.4–2.4  
yes 0.8 0.5–1.6  
FDG, n(%)   0.255 
neg 0.0 –  
pos 1.0 0.6–1.6  
SUV mean FDG   0.925 
<= 4.2 0.9 0.4–1.8  
> 4.2 0.9 0.5–1.8  
DE FDG   0.390 
<= 4.0 0.7 0.3–1.5  
> 4.0 1.1 0.5–2.2  
WB-B-MB FDG   0.835 
<= 17.6 0.8 0.4 –1.7  
> 17.6 0.9 0.4–2.0  
FES, n(%)   <
0.001 
Neg 2.9 1.2–7.0  
Pos 0.7 0.4–1.2  
SUV mean FES   0.018 
<= 3.4 1.4 0.8–2.4  
> 3.4 0.4 0.1–1.1  
DE FES   0.416 
<= 5.0 1.0 0.6–1.9  
> 5.0 0.7 0.3–1.6  
WB-B-MB FES   0.307 
<= 13.3 1.1 0.6–2.1  
> 13.3 0.7 0.3–1.5  
WB-B-MB ratio FES/FDG   0.005 
<= 1.1 1.6 0.9–2.8  
> 1.1 0.3 0.1–1.0  
Note 1: qualitative variables are dichotomized by using the median value. 
Note 2: p-values are referred to log-rank test. 
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observed in 30 of the 42 patients (71.4 %) with positive [18F]FES PET/ 
CT and 10 (23.8 %) died of disease. None of the three [18F]FDG PET/ 
CT-negative patients affected by documented bone metastases had 
died of disease by the end of follow-up. By contrast, 5 of the 7 patients 
with negative [18F]FES PET/CT and bone metastases had died of disease 
by the end of follow-up. 
Factors influencing PFS and OS are summarized in Tables 2 and 3 
respectively. Indeed, at univariate level, when the median value was 
considered as cut-off, no clinical or imaging risk factors influenced the 
PFS and only FES uptake and WB-B-MB ratio FES/FDG influenced the 
OS. 
The association between all prognostic PET parameters and 
progression-free survival is shown by the Kaplan-Meier curves in Fig. 2. 
In the multivariate analysis, according to the adjusted risk estimates 
for disease progression (Table 4), [18F]FDG-WB-B-MB proved directly 
associated to PFS. Specifically, patients with an [18F]FDG-WB-B-MB 
score >17.6 (median value) displayed a significantly higher risk of 
disease progression than those with an [18F]FDG-WBMB score ≤ 17.6 
[HR = 3.56, 95 %CI = (1.21–10.53), p = 0.022]. Moreover, borderline 
Fig. 2. Kaplan-Meier curves of progression-free survival and overall survival, stratified according to the median values of [18F]FDG-WB-B-MB and [18F]FES-WB-B- 
MB and the FES/FDG WB-B-MB Ratio). 
Table 4 
Cox Model for disease progression.  
PFS HR P value [95 % confidence interval] 
WB-B-MB FDG (>17.6 vs ≤17.6) 3.56 0.022 1.21− 11.53 
WB-B-MB FES (>13.3 vs ≤13.3 0.34 0.055 0.11− 1.03 
Age at diagnosis 1.02 0.241 0.99− 1.05 
Estrogen receptor expression (%) 1.01 0.480 0.99− 1.03 
Ki67 (%) 1.01 0.527 0.97− 1.05 
Visceral Metastases (y/n) 1.03 0.949 0.48− 2.21  
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significance was observed in the association between [18F]FES-WB-B- 
MB and PFS, with a lower risk in patients with an [18F]FES-WB-B-MB 
value above the median (median = 13.3) [HR = 0.34, 95 %CI 
=(0.11–1.03), p = 0.055] (Table 4). 
Kaplan-Meier curves for overall survival according to the prognostic 
factors are shown in Fig. 2. A significant association between FES/FDG 
WB-B-MB Ratio and OS was found (p = 0.01). This finding was 
confirmed by two multivariate Cox models on keeping the [18F]FDG- 
WB-B-MB (Table 5a) and F-FES-WB-B-MB (Table 5b) constant. It 
emerged that an FES/FDG ratio above the median (1.1) was associated 
with a lower risk of death [HR = 0.2, p = 0.01]. Fig. 3 depicts two ex-
amples of patients with opposing patterns of FDG and FES positivity. 
4. Discussion 
The present study investigated the biological substrate of suscepti-
bility to endocrine treatment in patients with bone metastases origi-
nating from BC. Indeed, one possible explanation for the unpredictable 
response and/or acquired resistance to endocrine therapy is the 
heterogeneity of ER expression (i.e., the contemporary presence of 
metastases and cellular clones with different degrees of ER expression). 
In our study, we focused our attention on patients with new evidence 
of bone metastases, and confirmed that pre-treatment molecular imag-
ing with [18F]FES-PET/CT is a very effective aid to evaluating the inter- 
lesion heterogeneity of bone metastases in patients with ER + BC [12]. 
Indeed, when combined with [18F]FDG-PET/CT, [18F]FES-PET/CT 
proved to be a powerful prognostic biomarker that was able to identify 
those patients at higher risk of disease progression and death. 
To quantify the heterogeneity of bone metastases on [18F]FES-PET/ 
CT and [18F]FDG-PET/CT, we introduced a reproducible and easily 
obtainable parameter (i.e. WB-B-MB), which is able to simultaneously 
provide information on the extension of bone disease and on the in-
tensity of tracer uptake. This index is able to capture the disease burden 
together with the rate of ER expression and glycolytic activity. To the 
best of our knowledge, no dedicated bone PET/CT scoring system has 
been developed that can correctly and automatically identify patients 
affected by bone metastases and stratify the risk of disease progression 
or death. The WB-B-MB is very easy to implement, can be calculated in 
every Nuclear Medicine Department, and has already been validated as a 
prognostic factor in patients with bone metastases [19,22]. 
By using the WB-B-MB, we confirmed that [18F]FDG-PET/CT was 
significantly associated with disease progression, high glycolytic activity 
often being the expression of high tumour grade and, more in general, of 
biological aggressiveness [19,23,24]. In addition, for the first time to our 
knowledge, we proved that the ratio between the WB-B-MB of FES and 
that of FDG could better quantify the heterogeneity of bone metastases 
and was the most powerful prognostic factor associated to OS when 
compared with the other clinical, histological and imaging parameters. 
Indeed, we found that the lower this WB-B-MB Ratio was (i.e <1.1) the 
higher the probability of dying of disease was. 
Although [18F]FES-PET/CT has proved effective as a predictor of 
response to endocrine therapy, particularly in those with evidence of 
high oestrogen receptor density [11,25–29], little can be said about its 
prognostic role, especially in patients with bone lesions. One study 
evaluated this issue, but no conclusive results concerning the prognostic 
role of [18F]FES-PET/CT were reported [17]. A previous paper, how-
ever, reported that the density of ER expression was influenced by the 
treatment scheme: in a single-case report, a drop in ER expression was 
observed after first-line tamoxifen/anastrazole; this was followed by a 
Table 5 
A, Cox model for OS (WB-B-MB RATIO FES/FDG adjusted for WB-B-MB FDG and 
dichotomized by median); B, Cox model for OS (WB-B-MB RATIO FES/FDG 
adjusted for WB-B-MB FES and dichotomized by median).  
Model A HR P 
value 
[95 % confidence 
interval] 
WB-B-MB Ratio FES/FDG (>1.1 
vs≤1.1) 
0.16 0.008 0.04− 0.62 
WB-B-MB FDG 1.00 0.600 0.99− 1.01 
Age at diagnosis 0.99 0.512 0.95− 1.03 
Estrogen receptor expression (%) 1.01 0.687 0.98− 1.04 
Ki67 (%) 1.01 0.674 0.95− 1.08 
Visceral Metastases (y/n) 1.29 0.672 0.39− 4.27  
Model B H.R. P 
value 
[95 % confidence 
interval] 
WB-B-MB Ratio FES/FDG (>1.1 
vs≤1.1) 
0.18 0.014 0.05− 0.71 
WB-B-MB FES 1.00 0.678 0.99− 1.01 
Age at diagnosis 0.99 0.512 0.95− 1.03 
Estrogen receptor expression (%) 1.01 0.742 0.97− 1.04 
Ki67 (%) 1.02 0.623 0.95− 1.08 
Visceral Metastases (y/n) 1.36 0.605 0.43− 4.33  
Fig. 3. 53-year-old woman affected by ER + BC bone metastases. [18F]FDG PET/CT (a) detected more bone metastases than [18F]FES PET/CT (b); the FES/FDG WB- 
B-MB ratio calculated was 0.79. The patient suffered disease progression and died of disease 20 months later. 60-year-old woman affected by ER + BC bone me-
tastases. [18F]FDG PET/CT (c) detected fewer bone metastases than [18F]FES PET/CT (d); the FES/FDG WB-B-MB ratio calculated was 3.7. The patient did not suffer 
disease progression over time (i.e. 37 months) and is still alive. 
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resurgence when the patient was switched to cytotoxic treatment [30]. 
This finding allowed a further therapeutic switch from chemotherapy to 
a second-line hormone therapy, which was effective in achieving a 
response. Albeit isolated, this report might provide a key to interpreting 
the lack of association between FES expression and survival: the receptor 
profile appears to be dynamic and influenced by the hormonal treat-
ment, which induces an internalization of ER and selects those cells 
without hormone receptor expression. Therefore, when trying to discern 
a correlation between FES PET and survival parameters, multiple 
time-points could be needed. Accordingly, in our study we did not find 
any significant correlation between [18F]FES-PET/CT-associated pa-
rameters (DE and WB-B-MB) and OS. However, we found that, by 
combining the information derived from [18F]FES-PET/CT with that 
yielded by [18F]FDG-PET/CT, we could obtain a reliable parameter, i.e. 
the FES/FDG WB-B-MB ratio, that could estimate the heterogeneity of 
bone metastases and therefore predict outcome. 
Although our results are encouraging, some limitations should be 
borne in mind. First, this study was performed in a relatively limited 
number of patients, and the data were retrospectively analysed. How-
ever, all patients were prospectively enrolled in a clinical trial that only 
included ER+, HER 2-negative MBC patients with a new diagnosis of 
distant metastases. In this setting, the risk of selection bias seems to be 
limited. 
Second, three different PET/CT scanners in three different Nuclear 
Medicine Departments were used to acquire PET images. Thus, the SUV 
of one PET/CT scanner might not be comparable to that of another, as 
the SUV is affected by the intrinsic characteristics of each PET/CT 
scanner. However, we used the same acquisition protocol and parame-
ters in all three Nuclear Medicine Departments. Moreover, since in-
strument assessment and quality control measures are critical to 
interpreting quantitative PET data, phantom acquisition images were 
previously collected in two of the three imaging centres, in order to set 
up the PET/CT scanners. 
Third, in the case of [18F]FES-PET/CT, the determination of WB-B- 
MB might not fully capture intra-patient and intra-metastatic hetero-
geneity in ER expression. This issue could be tackled by applying 
textural analysis to these images, in order to obtain information on the 
heterogeneity of the tissue. 
5. Conclusion 
Semi-quantification of [18F]FES-PET/CT and [18F]FDG-PET/CT 
performed at the time of first diagnosis of bone lesions in ER + BC pa-
tients is easy to perform and can identify the grade of metastatic het-
erogeneity, thereby providing important prognostic information in 
terms of OS. 
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